2024 ICD-10-CM Diagnosis Code Q85.1

Tuberous sclerosis

ICD-10-CM Code:
Q85.1
ICD-10 Code for:
Tuberous sclerosis
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Chronic
Code Navigator:

Code Classification

  • Congenital malformations, deformations and chromosomal abnormalities
    (Q00-Q99)
    • Other congenital malformations
      (Q80-Q89)
      • Phakomatoses, not elsewhere classified
        (Q85)

Q85.1 is a billable diagnosis code used to specify a medical diagnosis of tuberous sclerosis. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Angiofibroma
  • Ash leaf spot, tuberous sclerosis
  • Autosomal dominant polycystic kidney disease
  • Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
  • Benign neoplasm of nail apparatus
  • Fibrous skin tumor of tuberous sclerosis
  • Lymphangioleiomyomatosis due to tuberous sclerosis syndrome
  • Lymphangiomyomatosis of connective tissue
  • Macule of skin
  • Periungual fibroma
  • Periungual fibroma in tuberous sclerosis
  • Pulmonary lymphangioleiomyomatosis
  • Pulmonary tuberous sclerosis
  • Tuberous sclerosis syndrome
  • Tuberous sclerosis syndrome

Clinical Classification

Clinical Information

  • Tuberous Sclerosis

    autosomal dominant neurocutaneous syndrome classically characterized by mental retardation; epilepsy; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). there is, however, considerable heterogeneity in the neurologic manifestations. it is also associated with cortical tuber and hamartomas formation throughout the body, especially the heart, kidneys, and eyes. mutations in two loci tsc1 and tsc2 that encode hamartin and tuberin, respectively, are associated with the disease.
  • Tuberous Sclerosis Complex 1 Protein

    an intracellular signaling and tumor suppressor protein that forms a complex with tuberous sclerosis complex 2 protein (tsc2) and other signaling factors to negatively regulate mtorc1 signaling and affect cell growth and proliferation. structurally, it interacts with tsc2 through its n-terminal, which also contains gsk-3beta phosphorylation sites and a rho-kinase activation domain. it also contains a c-terminal coiled-coil domain and ezrin-radixin-moesin (erm) domain. mutations in the tsc1 gene are associated with tuberous sclerosis.
  • Tuberous Sclerosis Complex 2 Protein

    an intracellular signaling and tumor suppressor protein that forms a complex with tuberous sclerosis complex 1 protein (tsc1) and other signaling factors to negatively regulate mtorc1 and affect cell growth and proliferation. it can also function as gtpase-activating protein (gap) for rheb gtpase to activate mtorc1 independent of its role in the complex. structurally, it interacts with tsc1 through its n-terminus, which also contains a leucine zipper and coiled-coil region. it also has multiple phosphorylation sites for different cell signaling kinases, a central coiled-coil region, a c-terminal gap domain and calmodulin binding domain. mutations in the tsc2 gene are associated with tuberous sclerosis.
  • Angiofibroma

    a benign neoplasm of fibrous tissue in which there are numerous small and large, frequently dilated, vascular channels. (stedman, 25th ed)
  • Autosomal Dominant Polycystic Kidney Disease

    polycystic kidney disease inherited in an autosomal dominant pattern. symptoms usually appear at middle age and include abdominal pain, hematuria and high blood pressure. patients may develop brain aneurysms and liver cysts.
  • Autosomal Dominant Polycystic Kidney Disease Type 2

    autosomal dominant polycystic kidney disease caused by a mutation in pkd2.
  • Autosomal Dominant Polycystic Kidney Disease Type I

    autosomal dominant polycystic kidney disease caused by a mutation in pkd1.
  • Polycystic Kidney Disease, Infantile Severe, with Tuberous Sclerosis|Autosomal Dominant Polycystic Kidney Disease Type 1 with Tuberous Sclerosis|PKDTS|TSC2-PKD1 Contiguous Gene Deletion Syndrome

    an autosomal dominant condition caused by a contiguous gene deletion involving the pkd1 and tsc2 genes, encoding polycystin-1 and tuberin respectively. it is characterized by polycystic kidneys and tuberous sclerosis.
  • Polycystin-1|Autosomal Dominant Polycystic Kidney Disease Protein 1

    polycystin-1 (4303 aa, ~463 kda) is encoded by the human pkd1 gene. this protein may play a role in protein-protein and protein-carbohydrate interactions during kidney development.

Tabular List of Diseases and Injuries

The following annotation back-references are applicable to this diagnosis code. The Tabular List of Diseases and Injuries is a list of ICD-10-CM codes, organized "head to toe" into chapters and sections with coding notes and guidance for inclusions, exclusions, descriptions and more.


Inclusion Terms

Inclusion Terms
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
  • Bourneville's disease
  • Epiloia

Index to Diseases and Injuries References

The following annotation back-references for this diagnosis code are found in the injuries and diseases index. The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10-CM code(s).

Present on Admission (POA)

Q85.1 is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert Q85.1 to ICD-9-CM

  • ICD-9-CM Code: 759.5 - Tuberous sclerosis

Patient Education


Tuberous Sclerosis

Tuberous sclerosis is a rare genetic disease that causes benign tumors to grow in the brain and other organs. Symptoms vary, depending on where the tumors grow. They could include:

  • Skin problems, such as light patches and thickened skin
  • Seizures
  • Behavior problems
  • Intellectual disabilities
  • Kidney problems

Some people have signs of tuberous sclerosis at birth. In others it can take time for the symptoms to develop. The disease can be mild, or it can cause severe disabilities. In rare cases, tumors in vital organs or other symptoms can be life-threatening.

Tuberous sclerosis has no cure, but treatments can help symptoms. Options include medicines, educational and occupational therapy, surgery, or surgery to treat specific complications.

NIH: National Institute of Neurological Disorders and Stroke


[Learn More in MedlinePlus]

Tuberous sclerosis complex

Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the brain, kidneys, heart, skin, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person.

Tuberous sclerosis complex often affects the brain, with some affected individuals having benign growths in the outer surface of the brain (cerebral cortex) known as cortical tubers. Individuals with tuberous sclerosis complex often develop a pattern of behaviors called TSC-associated neuropsychiatric disorders (TAND). These disorders include hyperactivity, aggression, psychiatric conditions, intellectual disability, and problems with communication and social interaction (autism spectrum disorder). Additionally, individuals with tuberous sclerosis complex may have attention-deficit/hyperactivity disorder (ADHD) or seizures.

Kidney tumors are common in people with tuberous sclerosis complex; these growths can cause severe problems with kidney function and may be life-threatening in some cases. Additionally, tumors can develop in the heart (cardiac rhabdomyoma) and the light-sensitive tissue at the back of the eye (the retina). Some women with tuberous sclerosis complex develop lymphangioleiomyomatosis (LAM), which is a lung disease characterized by the abnormal overgrowth of smooth muscle-like tissue in the lungs that causes coughing, shortness of breath, chest pain, and lung collapse.

Virtually all affected people have skin abnormalities, including patches of unusually light-colored skin, areas of raised and thickened skin, and growths under the nails. Tumors on the face called facial angiofibromas are also common beginning in childhood. Sometimes, affected individuals have areas of bone or dental damage.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.